Evidence map›Paper›PMID 34367186›Full record

ArticleFrontiers in immunology2021

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation

Hua Zhu, Zhihong Jian, Yi Zhong, Yingze Ye, Yonggang Zhang, Xinyao Hu, Bei Pu, Lijuan Gu, Xiaoxing Xiong

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 1 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 1 synthesis or guideline pooled it, 333 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hua ZhuDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Zhihong JianDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yi ZhongDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yingze YeDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yonggang ZhangDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Xinyao HuDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Bei PuDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Lijuan GuCentral Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Xiaoxing XiongDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Wuhan University · CNRenmin Hospital of Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammatory responses play a multiphase role in the pathogenesis of cerebral ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses Methods: Rux, MCC950 or vehicle was applied to middle cerebral artery occlusion (MCAO) mice Results: Rux treatment improved neurological scores, decreased the infarct size and ameliorated cerebral edema 3 days after stroke. In addition, immunofluorescence staining and western blots showed that Rux application inhibited the expression of proteins related to the NLRP3 inflammasome and phosphorylated STAT3 (P-STAT3) in neurons and microglia/macrophages. Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-α, IFN-γ, HMGB1, IL-1β, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions Conclusion: JAK2 inhibition by Rux in MCAO mice decreased STAT3 phosphorylation, thus inhibiting the expression of downstream proinflammatory cytokines and the acetylation of histones H3 and H4 on the NLRP3 promoter, resulting in the downregulation of NLRP3 inflammasome expression.

Indexed as

AnimalsBrainCytokinesGene ExpressionHistonesInflammasomesInflammation MediatorsIschemic StrokeJanus Kinase 2Janus Kinase InhibitorsLymphocytesMacrophagesMiceNeuroinflammatory DiseasesNLR Family, Pyrin Domain-Containing 3 ProteinPromoter Regions, GeneticCytokinesHistonesInflammasomesInflammation MediatorsJak2 protein, mouseJanus Kinase 2Janus Kinase InhibitorsNLR Family, Pyrin Domain-Containing 3 ProteinStat3 protein, mouseSTAT3 Transcription Factorischemic strokeJAK2/STAT3neuroinflammationNLRP3 inflammasomeruxolitinib

Identifiers

PMID34367186
PMCPMC8339584
OpenAlexW3134875727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.